10-Q: CNO Financial Q2 Earnings Dip Amid Market Volatility

CNO Financial Group reports a decline in second-quarter net income and diluted earnings per share, primarily due to market-driven fair value adjustments, while reaffirming its full-year operating outlook.

Summary

• Net income for the six months ended June 30, 2025, was $113.3 million, a decrease from $228.6 million in the same period of 2024.
• Diluted earnings per common share for the six months ended June 30, 2025, was $1.11, down from $2.08 in the prior year.
• Net operating income (non-GAAP) for the six months ended June 30, 2025, was $168.6 million, a slight decrease from $172.1 million in the first six months of 2024.
• Total revenues for the six months ended June 30, 2025, decreased to $2,155.6 million from $2,222.7 million in the comparable period of 2024.
• Total benefits and expenses increased to $2,009.8 million in the first six months of 2025 from $1,925.9 million in the same period of 2024.
• Insurance product margin for the first six months of 2025 was $501.3 million, slightly down from $504.7 million in 2024. Excluding a traditional life model refinement, the margin was $494.5 million.
• Total net investment income increased 8% to $601.5 million for the first six months of 2025, up from $554.7 million in 2024.
• The expense ratio improved to 19.4% for the six months ended June 30, 2025, from 19.8% in the prior year.
• Collected premiums from annuity and interest-sensitive life products increased 14.1% to $1,089.0 million for the first six months of 2025.
• The estimated consolidated statutory Risk-Based Capital (RBC) ratio for U.S. based insurance subsidiaries was 378% at June 30, 2025, exceeding the target of 375%.
• Holding company unrestricted cash and cash equivalents were $187.1 million at June 30, 2025, above the minimum target of $150 million.
• The corporate debt to total capital ratio (excluding accumulated other comprehensive income (loss)) improved to 26.1% at June 30, 2025, from 32.1% at December 31, 2024.
• Repurchased 5.1 million shares of common stock for $199.9 million during the first six months of 2025.
• Increased quarterly common stock dividend to $0.17 per share from $0.16 per share in May 2025.

Sentiment

Score: 5

Explanation: The filing presents a mixed financial picture. While GAAP net income and EPS show a significant decline due to volatile non-operating items (fair value adjustments), the company's core operating income is relatively stable, and key capital management metrics (RBC, liquidity, debt-to-capital, share repurchases, dividend increase) are strong and within targets. The reaffirmed full-year operating outlook suggests confidence in underlying business performance, but the headline GAAP numbers are a clear negative.

Positives

• Operating Return on Equity (ROE) is on target for an approximate 50 basis point improvement in 2025 from the 2024 run rate of 10%.
• Total net investment income increased by 8% for the first six months of 2025 compared to the prior year, driven by growth in the business and higher yields.
• The expense ratio improved to 19.4% for the first six months of 2025, reflecting better operating leverage.
• Collected premiums from annuity and interest-sensitive life products increased by 14.1% for the first six months of 2025, primarily due to higher premium collections from fixed indexed annuity products.
• The estimated consolidated statutory RBC ratio of 378% at June 30, 2025, exceeded the targeted 375%.
• Holding company liquidity of $187.1 million at June 30, 2025, is above the minimum target of $150 million.
• The corporate debt to total capital ratio (excluding accumulated other comprehensive income (loss)) improved to 26.1% at June 30, 2025, from 32.1% at December 31, 2024, due to debt repayment.
• Repurchased $199.9 million of common stock and increased the quarterly common stock dividend to $0.17 per share, demonstrating strong capital deployment.
• Received formal IRS approval in March 2025 for a tax method change, recharacterizing $800 million of capitalized indirect costs to a Net Operating Loss (NOL) carryforward with no expiration date.

Negatives

• Net income for the six months ended June 30, 2025, decreased significantly to $113.3 million from $228.6 million in the prior year.
• Diluted earnings per common share decreased to $1.11 for the first six months of 2025 from $2.08 in the same period of 2024.
• Total revenues decreased to $2,155.6 million for the first six months of 2025 from $2,222.7 million in the prior year.
• Total benefits and expenses increased to $2,009.8 million for the first six months of 2025 from $1,925.9 million in the prior year.
• Net fee income decreased for the first six months of 2025 compared to the prior year, primarily due to the timing of income recognition on sales of third-party products and increased exchanges to newer carriers.
• Investment income not allocated to product lines decreased in the second quarter of 2025 due to lower option forfeitures, tighter spreads in the Federal Home Loan Bank (FHLB) program, and higher interest expense on higher average debt outstanding.
• The change in fair value of embedded derivative liabilities and market risk benefits resulted in a pre-tax loss of $44.4 million in the first six months of 2025, compared to a gain of $80.8 million in the prior year, contributing to the decline in net income.
• The Burnett v. Conseco Life Ins. Co. legal proceeding resulted in a notional jury verdict of approximately $0.2 million against the company for two class representatives, with further trials and appeals pending.

Risks

• General economic, market, and political conditions, including inflation, market volatility, tariffs, changes in tax laws, commodity prices, and foreign currency exchange rates, may affect investment values, capital raising, and refinancing costs.
• Exposure to interest rate risk, including volatility, may negatively impact results of operations, financial position, or cash flow.
• Future investment results, including realized losses and other-than-temporary impairment charges, may diminish invested assets and negatively impact profitability, financial condition, and liquidity.
• The ultimate outcome of lawsuits and other legal and regulatory proceedings, including potential for substantial or unspecified damages and class actions.
• Ability to make anticipated changes to non-guaranteed elements of life insurance products.
• Ability to obtain adequate and timely rate increases on health products, including long-term care business.
• Receipt of required regulatory approvals for dividend and surplus debenture interest payments from insurance subsidiaries.
• Mortality, morbidity, increased cost and usage of health care services, persistency, adequacy of previous reserve estimates, and changes in the health care market may affect the profitability of insurance products.
• Recoverability of deferred tax assets and the effect of potential ownership changes (e.g., Section 382 limitations) and tax rate changes on their value.
• The assumption that positions taken on tax return filings will not be successfully challenged by the IRS.
• Changes in accounting principles and their interpretation.
• Ability to continue to satisfy financial ratio and balance requirements and other covenants of debt agreements.
• Ability to identify products and markets to compete effectively against competitors with greater market share, higher ratings, greater financial resources, and stronger brand recognition.
• Ability to generate sufficient liquidity to meet debt service and cash needs.
• Changes in capital deployment opportunities.
• Ability to maintain effective controls over financial reporting and modeling.
• Ability to recruit and retain productive agents and distribution partners.
• Customer response to new products, distribution channels, and marketing initiatives.
• Inflation or other unfavorable economic or business conditions may impact sales and persistency of insurance products, medical coverage costs, and selling, general, and administrative expenses.
• Ability to maintain financial strength ratings of CNO and its insurance company subsidiaries, as well as the impact of ratings on business, capital access, and cost of capital.
• Regulatory changes or actions, including those relating to financial affairs of insurance companies (e.g., risk-based capital, minimum capital requirements, dividends), product sales/underwriting/pricing, healthcare regulation, and privacy laws.
• Changes in Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some products or affect the value of deferred tax assets.
• Availability and effectiveness of reinsurance arrangements, as well as the impact of any defaults or failure of reinsurers to perform.
• The use or anticipated use of artificial intelligence (AI) technologies by the company or third-parties.
• Performance of third-party service providers (domestic and international) and potential difficulties from outsourcing arrangements.
• Expectations for the growth rate of sales, collected premiums, annuity deposits, and assets.
• Interruption in telecommunication, information technology, or other operational systems, or failure to maintain the security, confidentiality, or privacy of sensitive data.
• Events of terrorism, natural disasters, or other catastrophic events, including potential adverse impacts from climate change.
• Cyber-security attacks, risk of data loss, and other security breaches.
• Ineffectiveness of risk management policies and procedures in identifying, monitoring, and managing risks.

Future Outlook

The company reaffirms its operating earnings per diluted share guidance in the range of $3.70 to $3.90, excluding significant items. It expects improved results in net investment income not allocated to product lines, assuming higher returns on alternative investments. A modest decrease in fee income is anticipated, with most earnings recognized in the fourth quarter of 2025 due to seasonality and Medicare Advantage sales volatility. The effective tax rate is expected to be generally consistent with prior years at approximately 23%. Excess cash flow to the holding company is projected to be in the range of $200 million to $250 million. The company aims to maintain a consolidated RBC ratio of 375% for U.S. based insurance subsidiaries, minimum holding company liquidity of $150 million, and a target debt to total capital (excluding accumulated other comprehensive income (loss)) of 25% to 28%. Operating ROE is expected to improve by 150 basis points through 2027 from a 10% run rate in 2024, including approximately 50 basis point improvement in 2025. The three-year TechMod project, costing approximately $170 million, will modernize technology, with the substantial majority of costs expensed as incurred and excluded from operating earnings.

Management Comments

• Our 2025 operating ROE is on target with our guidance of an approximate 50 basis point improvement from our 2024 run rate ratio of 10 percent.
• Total allocated and unallocated expenses in the first six months of 2025 were up slightly as compared to the same period in the prior year, and were in line with our expectations.
• We continue to invest in both our Medicare supplement products and Medicare Advantage distribution to meet our customers' needs and preferences.
• We are disciplined with our marketing expenditures and will increase or decrease our marketing spend depending on the current economics of the purchase or other factors.
• We expect to receive regulatory approval for future dividends from our subsidiaries, but there can be no assurance that such payments will be approved or that the financial condition of our insurance subsidiaries will not change, making future approvals less likely.
• We believe that the 375 percent RBC ratio target continues to adequately support our financial strength and credit ratings.
• We believe that the existing cash available to the holding company, the cash flows to be generated from operations and other transactions will be sufficient to allow us to meet our debt service obligations, pay corporate expenses and satisfy other financial obligations.

Industry Context

The company operates in the U.S. insurance sector, focusing on middle-income pre-retiree and retired Americans. The filing highlights the impact of rapid changes in global trade policies, including tariffs, and economic uncertainty on financial and economic conditions, leading to market volatility and inflation concerns. The company's strategy includes investing in Medicare supplement products and Medicare Advantage distribution, aligning with broader trends in the healthcare and senior markets. The industry faces ongoing regulatory scrutiny, particularly regarding financial affairs, product sales, and privacy laws.

Comparison to Industry Standards

• The company's estimated consolidated statutory RBC ratio of 378% at June 30, 2025, exceeds its targeted RBC ratio of 375% and the minimum 350% reflected in its risk appetite statement, indicating strong capital adequacy relative to internal benchmarks.
• Financial strength ratings from S&P ('A-'), Moody's ('A3'), AM Best ('A'), and Fitch ('A') for primary insurance subsidiaries indicate strong financial security characteristics, positioning the company favorably within the insurance industry, though some competitors may hold higher ratings.
• The corporate debt to total capital ratio (excluding accumulated other comprehensive income (loss)) improved to 26.1% at June 30, 2025, falling within the target range of 25% to 28%, suggesting prudent leverage management compared to industry best practices for financial stability.

Corporate Governance

Legal Proceedings

• Platinum Partners Value Arbitrage Fund L.P. (PPVA) case: Plaintiffs allege unjust enrichment from termination of reinsurance agreements and recapture of assets. CNO Parties are vigorously contesting. Trial scheduled for April 2026.
• Burnett v. Conseco Life Ins. Co.: Class action by former interest-sensitive whole life policyholders. A jury trial on causation and damages for two class representatives resulted in a notional verdict of approximately $0.2 million in favor of the class representatives on June 18, 2025. A bench trial on alter ego liability is scheduled for August 12, 2025. Further liability depends on the outcome of the alter ego trial and participation of absent class members in follow-on trials, all subject to appeal.
• Regulatory Examinations and Fines: Subject to various examinations, inquiries, and information requests from state, federal, and other authorities. The IRS is conducting an examination of 2016-2018 tax returns. Unfavorable outcomes could have a material adverse effect on business, financial condition, results of operations, or cash flows, and significant reputational harm.

Stakeholder Impact

• Shareholders: Impacted by decreased net income and EPS, but also benefit from share repurchases, increased dividends, and improved debt-to-capital ratio. Potential for future operating ROE improvement. Legal proceedings pose ongoing uncertainty.
• Policyholders: Financial strength is supported by strong RBC ratios and stable financial strength ratings, indicating the company's ability to meet obligations. The company continues to focus on serving middle-income pre-retiree and retired Americans.
• Employees: Affected by employee benefit plans and the TechMod project, which aims to modernize technology and potentially improve operational efficiency.
• Creditors: Debt obligations are being met, and the debt-to-capital ratio has improved, indicating a stronger financial position for creditors. The company maintains sufficient liquidity.
• Agents/Distribution Partners: Company continues efforts to recruit and retain productive agents and distribution partners. Changes in Medicare Advantage sales and carrier exchanges impact fee income for these partners.

Next Steps

• Monitor the outcome of the bench trial on alter ego liability in the Burnett v. Conseco Life Ins. Co. case, scheduled to begin on August 12, 2025.
• Observe the progress and financial impact of the three-year TechMod project, with approximately $45 million expected to be expensed in 2025.
• Track the recognition of fee income, with most earnings expected in the fourth quarter of 2025 due to seasonality and Medicare Advantage sales volatility.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements, with certain provisions effective in 2025 and others through 2027.
• Monitor the Platinum Partners Value Arbitrage Fund L.P. case, with trial scheduled to commence in April 2026.

Key Dates

Recommendation

While the GAAP net income and diluted EPS show a significant year-over-year decline, largely driven by non-operating fair value adjustments, the company's core operating performance remains relatively stable, and its operating earnings guidance has been reaffirmed. Strong capital management, evidenced by share repurchases, increased dividends, improved debt-to-capital ratio, and healthy RBC and liquidity levels, provides a solid foundation. Investors should monitor the volatility in non-operating items and the ongoing legal proceedings, but the underlying business appears to be executing on its strategy.

Keywords

Insurance, Annuity, Life Insurance, Health Insurance, SEC Filing, Financial Services, Quarterly Report, Investment Management, Risk Management, Corporate Governance, Share Repurchase, Dividends, SEC 10-Q, Financial Performance, Capital Resources, Policyholder Benefits, Market Risk, Tax Benefits, Legal Proceedings, Regulatory Compliance